help button home button
AJRCCM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tobin, M. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tobin, M. J.
American Journal of Respiratory and Critical Care Medicine Vol 169. pp. 301-313, (2004)
© 2004 American Thoracic Society
doi: 10.1164/rccm.2312007


Year in Review

Chronic Obstructive Pulmonary Disease, Pollution, Pulmonary Vascular Disease, Transplantation, Pleural Disease, and Lung Cancer in AJRCCM 2003

Martin J. Tobin

Division of Pulmonary and Critical Care Medicine, Loyola University of Chicago Stritch School of Medicine and Hines Veterans Affairs Hospital, Hines, Illinois

Correspondence and requests for reprints should be addressed to Martin J. Tobin. M.D., Division of Pulmonary and Critical Care Medicine, Hines Veterans Affairs Hospital, Route 111N, Hines, IL 60141. E-mail: mtobin2{at}lumc.edu


    CONTENTS
 TOP
 CONTENTS
 CHRONIC OBSTRUCTIVE PULMONARY...
 AIR POLLUTION
 PULMONARY VASCULAR DISORDERS AND...
 LUNG TRANSPLANTATION
 PLEURAL DISORDERS
 LUNG CANCER AND ONCOLOGIC...
 REFERENCES
 
Chronic Obstructive Pulmonary Disease (49)

  Epidemiology (3)

  Alpha1-Antitrypsin Deficiency (4)

  Cellular, Molecular, and Anatomical Abnormalities (12)

  Lung Inflammation (2)

  Exhaled Markers (3)

  Pathophysiologic and Radiologic Studies (1)

  Pulmonary Vasculature (1)

  Control of Breathing and Exercise (3)

  Respiratory Muscles (3)

  Peripheral Muscles (5)

  Drug Therapy (7)

    Theophylline (1)

    Glucocorticoids (4)

    New Drugs (2)

  Other Therapies (5)

    Lung Volume Reduction (1)

    Rehabilitation and Oxygen Therapy (3)

    Workshops and Review (1)

Air Pollution (4)

  General Air Pollution (2)

  Diesel Exhaust (2)

Pulmonary Vascular Disorders and Related Disorders (14)

  Pulmonary Hypertension (7)

    Secondary Pulmonary Hypertension (1)

    Molecular and Pathophysiologic Mechanisms (3)

    Diagnosis (1)

    Treatment (2)

  Thromboembolic Disorders (3)

  High Altitude (1)

  Sickle Cell Disease (3)

Lung Transplantation (10)

  Lung Preservation and Ischemia Reperfusion Injury (3)

  Obliterative Bronchiolitis (4)

  Rejection (2)

  In Lymphangiomyomatosis (1)

Pleural Disorders (6)

  Physiology/Pathophysiology (2)

  Diagnostic Techniques (3)

  Pleurodesis (1)

Lung Cancer and Oncologic disorders (12)

  Diagnosis (6)

  Studies of Molecular Mechanisms (1)

  Leukemia (1)

  Stem Cell Transplantation (4)


    CHRONIC OBSTRUCTIVE PULMONARY DISEASE
 TOP
 CONTENTS
 CHRONIC OBSTRUCTIVE PULMONARY...
 AIR POLLUTION
 PULMONARY VASCULAR DISORDERS AND...
 LUNG TRANSPLANTATION
 PLEURAL DISORDERS
 LUNG CANCER AND ONCOLOGIC...
 REFERENCES
 
Epidemiology
To determine whether obstructive airways disease is associated with sleep-disordered breathing, Sanders and coworkers (1) analyzed polysomnography and spirometry data from 5,954 participants in the Sleep Heart Health Study. Obstructive airway disease, defined as a ratio of forced expiratory volume in one second (FEV1) to forced vital capacity (FVC) of less than 70%, was present in 1,132 participants; involvement was mostly mild (FEV1/FVC, 63.8%). A respiratory disturbance index of greater than 10 events per hour was equally prevalent in subjects with obstructive airway disease and in subjects without obstructive airway disease, 22.3 versus 28.9%. In subjects without sleep apnea–hypopnea, the adjusted odds ratio for sleep desaturation (more than 5% of sleep time with saturation below 90%) exceeded 1.9 when FEV1/FVC was less than 65%. The authors conclude that mild obstructive airways disease is not associated with sleep apnea–hypopnea although an FEV1/FVC of less than 65% is associated with sleep desaturation. An editorial commentary by Fleetham (2) accompanies this article.

In a pulmonary perspective, Snider (3) discusses the nosology of chronic obstructive pulmonary disease (COPD).

Alpha1-Antitrypsin Deficiency
Gildea and coworkers (4) used a Markov-based decision model to assess the cost-effectiveness of augmentation therapy for severe {alpha}1-antitrypsin deficiency. A hypothetical cohort of 46-year-old patients with FEV1 of 49% predicted was followed over time using a Monte Carlo simulation. Treatment for life cost $895,243 and yielded 7.19 quality-adjusted life-years. Treatment until FEV1 was below 35% predicted cost $511,930 and produced 6.64 quality-adjusted life-years. No augmentation therapy costs $92,091 and yielded 4.62 quality-adjusted life-years. The incremental cost-effectiveness ratio was $207,841 per quality-adjusted life-year for augmentation therapy until FEV1 reached below 35% predicted and $312,511 for augmentation therapy for life. The cost of augmentation therapy needed to be reduced from $54,765 to $4,900 for augmentation therapy for life to be considered cost-effective. The authors conclude that augmentation therapy in patients with {alpha}1-antitrypsin deficiency is relatively cost-effective when compared with other conventionally used interventions.

Although serine elastase inhibitors have been proposed in the treatment of emphysema, little is known of their efficacy. To investigate this question, Churg and coworkers (5) studied transgenic mice that produce extremely low levels of human {alpha}1-antitrypsin and are tolerant to exogenous human {alpha}1-antitrypsin (Prolastin). Mice were exposed to daily cigarette smoke for up to 6 months, and some mice received human {alpha}1-antitrypsin every 48 hours. Treatment with {alpha}1-antitrypsin produced about a 2-fold increase in serum levels of {alpha}1-antitrypsin and elastase inhibitory capacity, and abolished smoke-induced increases in lavage neutrophils and matrix breakdown products (desmosine and hydroxyproline) at 2 to 30 days of smoke exposure. Oxidation of {alpha}1-antitrypsin (to remove antiproteolytic activity) did not increase serum elastase inhibitory capacity but did prevent influx of neutrophils. Treatment with {alpha}1-antitrypsin for 6 months provided 63% protection against airspace enlargement (emphysema) and abolished the increase in tumor necrosis factor-{alpha} mediated by smoke. The authors conclude that treatment with {alpha}1-antitrypsin ameliorates smoke-induced inflammation and matrix breakdown, possibly by suppressing tumor necrosis factor-{alpha}, and provides partial protection against emphysema. An editorial commentary by Stockley (6) accompanies this article.

The American Thoracic Society and the European Respiratory Society (7) present a statement on standards for the diagnosis and management of {alpha}1-antitrypsin deficiency.

Cellular, Molecular, and Anatomical Abnormalities
Fabbri and coworkers (8) asked, "Do patients with fixed airway obstruction have distinct pathologic and functional characteristics depending on whether they have asthma or COPD?". Twenty-seven patients with COPD and 19 patients with asthma had similar FEV1 (56% predicted in both groups) and airway hyperresponsiveness to methacholine (concentration producing a 20% decrease in FEV1: 2.8 versus 1.2 mg/ml). Compared with the patients who had COPD, the patients with asthma had more eosinophils in peripheral blood, sputum, bronchoalveolar lavage and airway mucosa; fewer neutrophils in sputum and bronchoalveolar lavage; a higher CD4+/CD8+ ratio of T cells infiltrating the airway mucosa; and a thicker reticular layer of the epithelial basement membrane. The patients with asthma had lower residual volume, higher diffusing capacity, higher exhaled nitric oxide, less emphysema on computed tomography, and greater responsiveness to bronchodilators and glucocorticoids. The authors conclude that patients with asthma and COPD have distinct pathologic and functional characteristics even when the degree of airway obstruction is equivalent.

To assess the role of neutrophilia and neutrophil chemokine and receptor gene expression in severe exacerbations of COPD, Qiu and coworkers (9) did endobronchial biopsies in 15 patients with COPD who were intubated for an acute exacerbation (FEV1, 36% of predicted), 7 patients with stable COPD (FEV1, 51% of predicted), and 15 control subjects intubated for a nonrespiratory surgical procedure (FEV1, 98% of predicted). Compared with the patients with stable COPD, the patients with an acute exacerbation of COPD had a 97-fold increase in neutrophilia; gene expression for epithelial-derived neutrophil attractant–78 (CXCL5) was increased 6-fold, interleukin-8 (CXCL8) was increased 6-fold, CXCR1 was increased 3-fold, and CXCR2 was increased 7-fold. In patients with an exacerbation of COPD, the number of neutrophils was correlated with cells positive for CXCR2 messenger RNA (r = 0.79), but not with cells positive for CXCR1 messenger RNA. Neutrophil number was not correlated with the duration of intubation or viral infection. The authors conclude that a severe exacerbation of COPD causes increased neutrophil recruitment that is associated with upregulation of the neutrophil-selective cytokines, CXCL5 (epithelial-derived neutrophil attractant–78) and CXCL8 (interleukin-8), and CXCR1 and CXCR2, the relevant receptors on which these neutrophil chemoattractant ligands act. An editorial commentary by Saetta and coworkers (10) accompanies this article.

Recent data reveal that both neutrophils and macrophage-derived metalloelastase (MMP-12) are required for the breakdown of connective tissue induced by acute cigarette smoke. Churg and coworkers (11) investigated the link between these mechanisms. Acute cigarette smoke exposure caused rapid increases in whole-lung activation of nuclear factor-{kappa}B and gene expression of proinflammatory cytokines in both wild-type mice (MMP-12+/+) and mice lacking metalloelastase (MMP-12–/–), thus indicating that absence of metalloelastase does not produce a global failure of the upregulation of inflammatory mediators. Only the wild-type mice demonstrated an increase in whole-lung tumor necrosis factor-{alpha} protein or the release of tumor necrosis factor-{alpha} from cultured alveolar macrophages exposed to smoke in vitro. Also, only wild-type mice exhibited increases in whole-lung E selectin, a marker of endothelial activation. The authors conclude that macrophage-derived metalloelastase (MMP-12) mediates smoke-induced inflammation by releasing tumor necrosis factor-{alpha} from macrophages, with subsequent endothelial activation, neutrophil influx, and proteolytic breakdown of the matrix caused by neutrophil-derived proteases, and that release of tumor necrosis factor-{alpha} may be a general mechanism whereby metalloproteases drive cigarette smoke–induced inflammation. An editorial commentary by Snider (12) accompanies this article.

Little is known about the pathogenesis of the small airway disease (a form of airway remodeling) in cigarette smokers. To better understand the mechanism, Wang and coworkers (13) exposed rat tracheal explants to cigarette smoke and then maintained them in an air–organ culture. At 24 hours after smoke exposure, gene expression of procollagen was increased in a dose-dependent manner and hydroxyproline, a measure of collagen content, was increased. Greater increases in gene expression of procollagen occurred with repeated smoke exposure. The increase in procollagen gene expression was prevented by a selective inhibitor of nuclear factor-{kappa}B activation (SN50), scavengers of active oxygen species (superoxide dismutase, catalase, and tetramethylthiourea), and an inhibitor of epidermal growth factor receptor signaling (AG1478), but not by inhibitors of mitogen-activated protein kinases (PD98059 and SB203580). The authors conclude that cigarette smoke directly induces airway wall fibrosis, probably through transactivation of the epidermal growth factor receptor (mediated by active oxygen species) and subsequent activation of nuclear factor-{kappa}B, and that the injury does not require smoke-evoked inflammatory cells.

Extracellular matrix metalloproteinase inducer (EMMPRIN) is present in the lung during development but expression in the healthy adult lung is minimal. To determine whether EMMPRIN might be associated with smoking-induced injury, Betsuyaku and coworkers (14) did bronchoalveolar lavages in 7 never-smokers, 16 former smokers, and 58 current smokers (7 of the former smokers and 32 of the current smokers had emphysema on computed tomography). Levels of EMMPRIN were higher in current smokers (315 pg per ml) and former smokers (175 pg per ml) than in never smokers (31 pg per ml); the levels did not discriminate between the presence or absence of emphysema among the smokers. Immunochemistry of smokers' lung tissue revealed EMMPRIN in bronchiolar epithelium and alveolar macrophages; messenger RNA for EMMPRIN in alveolar macrophages did not differ between current and never-smokers. Matrix metalloproteinase-1 was detected in bronchoalveolar fluid of some smokers, but not in the never-smokers. The authors conclude that smoking is associated with increases in extracellular matrix metalloproteinase inducer (EMMPRIN) in bronchoalveolar fluid and that the increase persists for a long time after smoking cessation.

Because glucocorticoids can affect matrix metalloproteinases, Choe and coworkers (15) studied the effect of methylprednisolone on lung structure in adult rats. Daily methylprednisolone (2 mg per kg) for 1, 2, or 4 weeks produced an increase in mean linear intercept and a decrease in the surface–volume ratio. Animals also exhibited increased activity of matrix metalloproteinase-9. Rats treated with a broad-spectrum matrix metalloproteinase inhibitor (GM6001) did not develop emphysema. The authors conclude that methylprednisolone increases the activity of matrix metalloproteinases in rat lung and causes emphysema.

In a state of the art review article, Ryu and colleagues (16) discuss bronchiolar disorders.

In a report from an international workshop, Jeffery and colleagues (17) describe the methods used for the assessment of endobronchial biopsies in clinical research, and the application of these methods in studies of pathogenesis and treatment.

In a state of the art review article, Kinnula and Crapo (18) discuss superoxide dismutase in lung disease.

In a pulmonary perspective, Turino and Cantor (19) discuss the role of hyaluronan in respiratory injury and repair.

Lung Inflammation
To determine whether the magnitude of bacterial colonization and airway inflammation influences decline in lung function, Wilkinson and coworkers (20) studied 30 patients with COPD (FEV1, 0.95 liter) over a period of 12 months. FEV1 declined by 57.6 ml over the 12 months. All sputum samples grew significant numbers of bacteria; quantitative bacteriology revealed an almost 3-fold increase in bacterial count over the period. Decline in FEV1 was correlated with bacterial load (r = 0.59). Decline in FEV1 was greater in patients who experienced a change in the type of colonizing bacteria than in patients who were colonized with a single bacterial species over the period: 102 versus 3.6 ml per year. Decline in FEV1 was greater in patients with high levels of interleukin-8 in sputum. The authors conclude that bacterial colonization is an important factor in the decline of lung function in patients with COPD, and that rising airway bacterial load and a change in bacterial species are associated with greater airway inflammation and accelerated decline in function.

In a mouse model of elastase-induced emphysema, Inoue and coworkers (21) investigated the mechanism for increased susceptibility to bacterial infection. Intratracheal infection with Streptococcus pneumoniae (103–107 cfu per mouse) increased mortality in a dose-dependent manner in emphysematous mice, but did not kill control mice. Compared with control mice, the emphysematous mice had lower levels of total cells, neutrophils, tumor necrosis factor-{alpha}, and macrophage inflammatory protein-2 in bronchoalveolar lavage. Histology revealed alveoli filled with inflammatory cells and exudates in the control mice, but not in the emphysematous mice. At 72 hours, the emphysematous mice had higher levels of serum cytokines, and significant numbers of S. pneumoniae in both lung tissue and blood. The authors conclude the experimental emphysema impairs the intra-alveolar, but not the systemic, immune response to bacterial infection.

Exhaled Markers
In 20 patients with COPD (FEV1, 52% of predicted), 20 nonsmoking control subjects, and 12 smoking control subjects, Corradi and coworkers (22) studied different classes of aldehydes in exhaled breath condensates. Compared with nonsmoking control subjects, the patients had higher levels of malondialdehyde (57.2 versus 17.7 nmol per liter), hexanal (63.5 versus 14.2 nmol per liter), and heptanal (26.6 versus 18.7 nmol per liter). Only malondialdehyde was higher in the patients than in smoking control subjects (57.2 versus 35.6 nmol per liter). The authors conclude that malondialdehyde, hexanal, and heptanal are higher in exhaled breath condensate of patients with COPD than in nonsmoking control subjects, but only malondialdehyde is higher in patients than in smoking control subjects. An editorial commentary by Risby (23) accompanies this article.

The use of exhaled breath condensates for assessing lung inflammation is complicated by dilution from varying amounts of water vapor. In 18 healthy subjects, Effros (24) determined whether conductivity of lyophilized samples can be used for estimating airway electrolyte concentrations and dilution of exhaled condensates by water vapor. The dilution was estimated by comparing concentrations of nonvolatile, reference indicators (total nonvolatile cations, urea, or conductivity), and assuming that concentrations in respiratory fluid and plasma are equivalent. The volatile cation, ammonium (NH4+), represented 93% of cations in the condensate. More than 99% of ammonium was removed by lyophilization, making it possible to use conductivity to estimate total nonvolatile ionic concentrations and facilitating analysis of urea. Estimates of dilution were equivalent for total cations (20,472), conductivity (21,019), and urea (18,818). The authors conclude that measurement of conductivity in lyophilized samples of exhaled breath condensates makes it possible to estimate the dilution of condensates by water vapor.

Pathophysiologic and Radiologic Studies
In a pulmonary perspective, Suki and colleagues (25) discuss the role of proteases, inflammation, and mechanical forces on the progression of emphysema.

Pulmonary Vasculature
To determine whether vascular endothelial growth factor contributes to the pulmonary vascular changes in patients with COPD, Santos and coworkers (26) obtained surgical specimens from 10 patients with severe emphysema, 28 patients with moderate COPD, 21 smokers with normal lung function, and 19 nonsmokers. Immunohistochemical expression of vascular endothelial growth factor was greater in the pulmonary arteries of patients with moderate COPD (77%) and smokers (68%) than in the pulmonary arteries of nonsmokers (53%). Expression of vascular endothelial growth factor was correlated with the thickness of the vessel wall (r = 0.38). Protein content of vascular endothelial growth factor in lung tissue was reduced in severe emphysema, and the proportion of the VEGF189 isoform was lower. The authors conclude that expression of vascular endothelial growth factor in pulmonary arteries varies according to the severity of COPD.

Control of Breathing and Exercise
To determine the effect of exercise capacity and health status on mortality in patients with COPD, Oga and coworkers (27) followed 150 men with COPD (postbronchodilator FEV1, 47% of predicted) over 5 years. After 5 years, 31 of the 144 patients available for analysis had died. Three sets of Cox proportional hazard analyses were performed. Univariate analysis revealed the mortality was correlated with the St. George's Respiratory Questionnaire and with the Breathing Problems Questionnaire, but not with the Chronic Respiratory Disease Questionnaire. Multivariate analysis revealed that mortality was correlated with peak oxygen uptake during progressive cycle ergometry and with the St. George's Respiratory Questionnaire, independent of FEV1 and age. Stepwise analysis revealed that peak oxygen uptake was the most significant predictor of mortality. The authors conclude that exercise capacity and health status predict mortality in patients with COPD, and that the St. George's Respiratory Questionnaire and the Breathing Problems Questionnaire were stronger predictors than was the Chronic Respiratory Disease Questionnaire.

To examine factors influencing the reproducibility of the 6-minute walk test, Sciurba and coworkers (28) analyzed data on the first 761 patients entered into the National Emphysema Treatment Trial. Of these, 470 patients repeated the walk on the next day. Patients walked 7% more (66 ft) on the second day; intraclass correlation coefficient was 0.88 between days. Patients walking on a circular or oval course walked 92 ft more than did patients walking on a straight course. Course length had no effect on walking distance. The authors conclude that the training effect during a 6-minute walk test is less than previously reported, and that layout of the track influences the distance walked

The American Thoracic Society and the American College of Chest Physicians (29) present a statement on cardiopulmonary exercise testing.

Respiratory Muscles
The adaptive response of inspiratory muscles to increased workloads includes increases in oxidative enzymes and changes in expression of contractile proteins, but the effect on mitochondrial function is not known. To study the in situ properties of mitochondria of respiratory muscles, Ribera and coworkers (30) obtained biopsies of the costal diaphragm and external intercostals in 9 patients with emphysema and in 11 control subjects. Maximal oxidative capacity was 135% higher in the diaphragm and 37% higher in the external intercostals in the patients than in the control subjects. Maximal oxidative capacity was correlated with percent predicted FEV1 (diaphragm: r = –0.64; intercostals: r = –0.67) and with the ratio of residual volume to total lung capacity (diaphragm: r = 0.64; intercostals: r = 0.63). The slow myosin heavy chain isoform was increased in the diaphragm of the patients. The authors conclude that maximal respiration of mitochondria is increased in both the diaphragm and external intercostal muscles of patients with emphysema, and that the associated improvement in the coupling of oxidation to phosphorylation suggests increased efficiency of ATP production by mitochondria.

To determine the relationship between diaphragmatic fiber type and severity of airway obstruction, Levine and coworkers (31) did biopsies of the costal diaphragm in 40 patients with COPD (FEV1 ranged from 16 to 118% of predicted). The relationship between the proportion of pure Type I fibers and FEV1 was exponential (r = 0.844): the proportion showed little increase as FEV1 decreased from 118 to 60% of predicted, but thereafter increased appreciably. Patients with severe COPD exhibited lower levels of maximal specific force in single fibers than did patients with normal lung function. Type I fibers generated lower force than did Type II fibers. The authors conclude that patients with COPD develop an increase of Type I fibers in their costal diaphragm when FEV1 falls below 60% of predicted and that force generation is also decreased secondary to adaptations within each fiber type.

In a state of the art review article on disorders of the respiratory muscles, Laghi and Tobin (32) discuss the effect of COPD on the respiratory muscles.

Peripheral Muscles
To determine whether the development of quadriceps fatigue during exercise influences the response to a bronchodilator, Saey and coworkers (33) studied 18 patients with COPD (FEV1, 38% predicted). Compared with placebo, inhalation of ipratropium bromide (500 µg) tended to increase the time that cycle exercise was endured at a constant work rate: 440 versus 322 seconds. Nine patients developed quadriceps fatigue (a decrease in quadriceps twitch pressure of more than 15%) secondary to exercising after placebo; ipratropium did not increase endurance time in these patients despite an increase in FEV1 of 11%. Nine patients did not develop quadriceps fatigue secondary to exercising after placebo; ipratropium increased endurance time in these patients (479 versus 249 seconds). The improvement in endurance time with ipratropium was correlated with twitch force of the quadriceps at 10 minutes after exercise preceded by placebo (r = 0.59). The authors conclude that the development of quadriceps fatigue may explain why some patients with COPD fail to increase endurance time after ipratropium. An editorial commentary by Casaburi (34) accompanies this article.

Oxidative stress arising in exercising muscle may contribute to the peripheral muscle dysfunction of COPD. To determine whether quadriceps exercise induces oxidative stress and whether the stress decreases muscle endurance, Couillard and coworkers (35) studied 12 patients with COPD (FEV1, 33% predicted) and 10 healthy subjects. Biopsies of the vastus lateralis were obtained before and 48 hours after exercise. Quadriceps endurance was less in the patients than in the control subjects: 378 versus 843 seconds. At 48 hours, patients, but not the control subjects, displayed increases in muscle lipid peroxidation and oxidized protein; the control subjects, but not the patients, displayed an increase in peroxidase glutathion activity. Endurance time was inversely correlated with both muscle lipid peroxidation (r = –0.66) and oxidized protein (r = –0.70). The authors conclude that quadriceps exercise increased oxidative stress but not antioxidant activity in patients with COPD, and that the increase in oxidative stress was correlated with a decrease in quadriceps endurance.

To determine whether severity of COPD influences the degree of quadriceps fatigability after single muscle contractions, Mador and coworkers (36) studied 8 patients with severe COPD (FEV1, 26% predicted), 11 patients with mild-to-moderate COPD (FEV1, 50% predicted), and 10 healthy subjects. Maximum voluntary contraction of the right quadriceps achieved a force of 44 kg in patients with severe COPD, 49 kg in patients with mild-to-moderate COPD, and 58 kg in healthy subjects. Three sets of 10 maximum voluntary contractions of the quadriceps achieved greater fatigability (measured as the decrease in potentiated twitch force during magnetic stimulation of the femoral nerve) of the quadriceps in patients with severe COPD than in patients with mild-to-moderate COPD or the healthy subjects. The fall in twitch force in patients with mild-to-moderate COPD was not significantly different from healthy subjects. The authors conclude that patients with severe COPD display greater fatigability of the quadriceps muscle than do healthy subjects or patients with mild-to-moderate COPD.

When cycling, patients with COPD often stop because of leg effort rather than dyspnea. To determine whether the response might differ when patients walk versus when they cycle, Man and coworkers (37) studied 84 patients with COPD (FEV1, 41% of predicted). Dyspnea alone was a more common limiting symptom during incremental walking than during incremental cycling (81 versus 34%) and during endurance walking than during endurance cycling (75 versus 29%). Twitch stimulation of the quadriceps was performed in 12 of the patients. Walking did not decrease twitch tension of the quadriceps, whereas cycling caused a 17.1% decrease in twitch tension. The authors conclude that leg effort and fatigue of the quadriceps are infrequent after walking in patients with COPD.

Drug Therapy
Theophylline.
In a pulmonary perspective, Barnes (38) presents new thoughts on theophylline.

Glucocorticoids.
Recent observational cohort studies suggest that inhaled glucocorticoids may decrease morbidity and mortality in patients with COPD after hospital discharge. To determine whether the conclusions are distorted by an immortal time bias, Suissa (39) analyzed data from a population-based cohort of Saskatchewan residents, 55 years or older, who were first hospitalized for COPD between 1990 and 1997. Of 979 patients followed for 1 year after hospital discharge for COPD, 389 died or were rehospitalized for COPD. During the first 90 days after discharge, 383 patients received inhaled glucocorticoids. With time-fixed analysis, the rate of readmission or death (events per 100 per year) was 42 among glucocorticoid users and 63 among nonusers. With corrected, time-dependent analysis, the rate of readmission or death was 47 among glucocorticoid users and 59 among nonusers. The rate of readmission or death was affected markedly by the time available for receiving a glucocorticoid prescription in the time-fixed analysis; this effect was not observed with the corrected, time-dependent analysis. Use of inhaled glucocorticoids after hospitalization for COPD did not affect morbidity or mortality. The author concludes that an immortal time bias in previous observational studies has produced a misleading impression that inhaled glucocorticoids decrease morbidity and mortality after hospitalization for COPD. An editorial commentary by Samet (40) accompanies this article.

Although observational studies in patients with COPD have revealed improved survival with use of inhaled glucocorticoids, the benefit has not been seen with randomized trials. One explanation for the discrepancy is the misclassification of users and nonusers because of immortal person–time bias; this bias arises because some patients will have died at the point of assessing glucocorticoid exposure, and thus patients who survive will have a longer opportunity for being exposed to glucocorticoids. To avoid the problem of immortal person–time bias, Fan and coworkers (41) analyzed pharmacy refill records in 2,686 patients with COPD in a time-dependent manner. Mortality was not significantly decreased for average inhaled glucocorticoid use at either low dose (hazard ratio, 0.96) or medium/high dose (hazard ratio, 0.86). Likewise, mortality was not significantly decreased with recent inhaled glucocorticoid use at low dose (hazard ratio, 0.80) or medium/high dose (hazard ratio, 0.88). Use of inhaled glucocorticoids was not associated with hospitalizations or exacerbations secondary to COPD. The authors conclude that use of inhaled glucocorticoids, either in terms of dosage or length of use, is not associated with either exacerbations of COPD or mortality from COPD.

To determine the effect of glucocorticoids on cytokine release by alveolar macrophages, Culpitt and coworkers (42) did bronchoalveolar lavage in 15 patients with COPD (FEV1/FVC, 53%) and 15 cigarette smokers without airway obstruction. Basal release of interleukin-8 by macrophages was more than five times greater in the patients than in the smokers; release of granulocyte macrophage-colony stimulating factor was equivalent in the two groups. Both interleukin-1ß and cigarette smoke media increased the release of both interleukin-8 and granulocyte macrophage-colony stimulating factor from both the patients and the smokers. Dexamethasone did not inhibit the basal level or the stimulated release of interleukin-8 from the macrophages of the patients, although it inhibited release in the smokers. Dexamethasone inhibited both the basal release of granulocyte macrophage-colony stimulating factor and the release induced by interleukin-1ß, but it did not inhibit the release induced by cigarette smoke media. The authors conclude that the lack of efficacy of glucocorticoids in COPD might be secondary to relative insensitivity of macrophages in the respiratory tract to glucocorticoids.

New drugs.
Cilomilast is a new selective inhibitor of phosphodiesterase-4. Gamble and coworkers (43) did a randomized trial of cilomilast (15 mg twice daily) or placebo for 12 weeks in 59 patients with COPD. Cilomilast had no effect on FEV1 or differential cell counts of induced sputum (obtained during five visits). Cilomilast resulted in decreases in CD8+ and CD68+ cells in bronchial biopsies. Compared with placebo, cilomilast produced a 48% decrease in CD8+ cells and a 47% decrease in CD68+ cells. The authors conclude that cilomilast, a selective phosphodiesterase-4 inhibitor, decreases tissue CD8+ T lymphocytes and CD68+ monocytes/macrophages in patients with COPD. An editorial commentary by Kerstjens and Timens (44) accompanies this article.

Other Therapies
Lung volume reduction.
Bronchoscopic lung volume reduction achieves collapse of targeted lung regions using a washout solution to disrupt surfactant function and a tissue sealant to prevent reexpansion. Ingenito and coworkers (45) evaluated this procedure in six sheep with papain-induced emphysema. Features of emphysema included 8% increase in total lung capacity, 66% increase in residual volume, and 76% increase in airway resistance. Bronchoscopic lung volume reduction decreased total lung capacity by 16%, decreased residual volume by 55%, and increased vital capacity by 10%. At autopsy, well organized peripheral scars associated with tissue contraction were observed in 91% of the 36 treated sites. The procedure was tolerated without complications, and there was no evidence of infection, abscess, granuloma formation, or allergic reaction. The authors conclude that bronchoscopic lung volume reduction improved pulmonary function consistently and safely in sheep with experimental emphysema.

Rehabilitation and oxygen therapy.
In 29 patients with nonhypoxemic COPD (FEV1, 36% of predicted), Emtner and coworkers (46) did a double-blind trial to determine whether administration of supplemental oxygen during exercise training achieves a higher training work rate and thereby improves exercise capacity. The patients exercised on cycle ergometers for 45 minutes, 3 times a week for 7 weeks, at high-intensity targets while receiving 3 liters per minute of either oxygen or compressed air. Both groups had higher exercise tolerance after training. The oxygen-trained group, however, increased the training work rate more rapidly than did the air-trained group. Work rate during the last week was higher in the oxygen-trained group than in the air-trained group: 62 versus 52 watts. After training, endurance during constant work rate increased more in the oxygen-trained group than in the air-trained group: 14.5 versus 10.5 minutes. At isotime, respiratory rate decreased more in the oxygen-trained group than in the air-trained group: decrease of 4 versus 1 breath per minute. The authors conclude that administration of supplemental oxygen during high-intensity training produces a higher intensity of training and greater exercise tolerance during laboratory testing. An editorial commentary by Brusasco and Pellegrino (47) accompanies this article.

Maintaining long-term improvement after pulmonary rehabilitation has been difficult. In 172 patients with chronic lung disease, Ries and coworkers (48) tested the value of a telephone–maintenance program after rehabilitation in a randomized trial. Patients were randomized to 12 months of maintenance intervention (weekly phone calls plus monthly supervised reinforcement session) or standard care, and followed for 24 months. During the 12 months of intervention, the maintenance intervention group achieved better exercise tolerance (maximum treadmill workload and 6-minute walk distance), better overall health status ratings, and a decrease in hospital days. The groups did not differ in measures of pulmonary function, dyspnea, self-efficacy, quality of life, or general health use. By 24 months, group differences were no longer present and patients returned to levels close to, but above, prerehabilitation measures. The authors conclude that a maintenance program of weekly telephone calls and monthly supervised sessions only modestly enhance the maintenance of benefits after pulmonary rehabilitation.

Workshops and review articles.
In a summary report from a National Heart, Blood, and Lung Institute Workshop, Croxton and colleagues (49) discuss needs for opportunities for research on COPD.


    AIR POLLUTION
 TOP
 CONTENTS
 CHRONIC OBSTRUCTIVE PULMONARY...
 AIR POLLUTION
 PULMONARY VASCULAR DISORDERS AND...
 LUNG TRANSPLANTATION
 PLEURAL DISORDERS
 LUNG CANCER AND ONCOLOGIC...
 REFERENCES
 
General Air Pollution
To determine whether the presence of a contributing respiratory disease increases the effect air pollution on mortality from nonrespiratory disease, De Leon (50) modeled the short-term association between ambient particulate matter (10 µm or less in aerodynamic diameter) and mortality in New York City between 1985 and 1994. Compared with subjects without a contributing respiratory disease, the subjects who had a contributing respiratory disease had higher mortality for circulatory deaths (relative risk, 1.066) and cancer deaths (relative risk, 1.129). The relationships were observed only in subjects who were 75 years of age or older. The authors conclude that older individuals are at increased risk of mortality from air pollution when coexisting respiratory disorders are also present.

The American Thoracic Society (51) presents a document on lung diseases and the environment.

Diesel Exhaust
Because short-term increases in particulate air pollution are associated with cardiovascular events and because the intratracheal instillation of diesel exhaust particles are prothrombotic, Nemmar and coworkers (52) studied the time course of the prothrombotic effect and its relationship to lung inflammation. Instillation of 50 µg of diesel exhaust particles in hamsters induced increases in venous thrombosis of 480% at 1 hour, 770% at 6 hours, and 460% at 24 hours. Levels of neutrophils and histamine were increased at all times in bronchoalveolar lavage. In plasma, histamine was increased at 6 and 24 hours but not at 1 and 3 hours. Pretreatment with a histamine H1–receptor antagonist (diphenhydramine) abolished the influx of neutrophils in bronchoalveolar lavage at all time points. The histamine antagonist did not affect the thrombosis or platelet activation induced by the diesel exhaust particles at 1 hour, but it markedly decreased both actions at 6 and 24 hours. The authors conclude that intratracheal instillation of diesel exhaust particles induces peripheral venous thrombosis that is correlated with pulmonary inflammation at 6 and 24 hours but not at 1 hour (at this point, the prothrombotic action may result from penetration of the particles or associated components into the bloodstream).

Senechal and coworkers (53) investigated whether diesel exhausts favor type 2 helper T cell (Th2)–associated allergic reactions either by increasing production of Th2-associated chemokines and their associated receptors or by decreasing type 1 helper T cell (Th1)–attracting chemokines and chemokine receptors. Exposure of peripheral blood mononuclear cells from patients with asthma to diesel induced release of I-309; this effect did not occur with allergen exposure. Both diesel and Der p 1 induced early but transient release of monokine induced by interferon-{gamma} and late release of pulmonary- and activation-regulated chemokine. Both Th1- and Th2-attracting chemokines were induced, but the resulting effect was increased chemotactic activity of Th2 cells and not of Th1 cells. Diesel induced a late increase in the expression of the Th1-associated CXC receptor 3 and CC receptor 5. Upregulation of T cell CXC receptor 3 was not associated with increased migration to its ligands. The authors conclude that diesel, even in the absence of allergen, amplifies Th2 immune response and that it also increases late Th1-associated chemoreceptor expression.


    PULMONARY VASCULAR DISORDERS AND RELATED DISORDERS
 TOP
 CONTENTS
 CHRONIC OBSTRUCTIVE PULMONARY...
 AIR POLLUTION
 PULMONARY VASCULAR DISORDERS AND...
 LUNG TRANSPLANTATION
 PLEURAL DISORDERS
 LUNG CANCER AND ONCOLOGIC...
 REFERENCES
 
Pulmonary Hypertension
Secondary pulmonary hypertension.
Nunes and coworkers (54) reported a series of 82 patients with human immunodeficiency virus (HIV)–associated pulmonary arterial hypertension. Pulmonary hypertension was the direct cause of death in 72% of the patients. Survival rate in the overall population was 73% at 1 year, 60% at 2 years, and 47% at 3 years. Compared with New York Heart Association functional Class I-II, patients in functional Class III-IV at the time of diagnosis had lower survival rates at 1 year (60 versus 100%), 2 years (45 versus 90%), and 3 years (28 versus 84%). In patients with functional class III-IV, univariate analysis revealed that prognosis was related to CD4 lymphocyte count of more than 212 cells mm–3, use of combination antiretroviral therapy, and use of epoprostenol. Multivariate analysis revealed CD4 lymphocyte count as the only independent predictor of survival, probably because combination antiretroviral therapy and epoprostenol therapy were linked in these patients. The authors conclude that pulmonary artery hypertension has an independent negative effect on prognosis in patients with HIV infection, and that epoprostenol should be considered in the treatment of patients with severe pulmonary hypertension.

Molecular and pathophysiologic mechanisms.
Pulmonary veno-occlusive disease is a rare form of pulmonary hypertension, which originates in small pulmonary veins and venules, and its relationship to primary pulmonary hypertension is unclear. Runo and coworkers (55) describe a patient with pulmonary veno-occlusive disease whose mother had severe pulmonary hypertension. When the coding region of the patient's bone morphogenetic protein receptor II (BMPR2) gene was sequenced, it revealed a del44C mutation in Exon 1, which is predicted to encode for a truncated protein (mutations in the BMPR2 gene have been identified in half of familial cases and a quarter of sporadic cases of primary pulmonary hypertension). Analysis of DNA from family members indicated that this mutation was transmitted by the proband's mother to two of her four children. The authors conclude that the association between pulmonary veno-occlusive disease and mutation of BMPR2 reveals a possible pathogenetic link with primary pulmonary hypertension.

The mitogenic effect of serotonin on smooth muscle cells of the pulmonary vasculature is mediated by the serotonin transporter, 5-hydroxytryptamine transporter (5-HTT); the constricting effect of serotonin is mediated by the receptors, 5-HT1B/1D and 5-HT2A. Marcos and coworkers (56) investigated the role of the serotonin transporter and receptors on the development of pulmonary hypertension in mice exposed to chronic hypoxia (10% oxygen for 2 weeks). Development of right-ventricular hypertrophy was decreased by 12% with citalopram and by 14% with fluoxetine, two inhibitors of the serotonin transporter (5-HTT); pulmonary vessel muscularization was also decreased with both treatments. Two receptor antagonists, GR127935 (selective antagonist of 5-HT1B/1D) and ketaneserin (selective antagonist of 5-HT2A) had no effect on right-ventricular hypertrophy or pulmonary vessel muscularization. The authors conclude that the serotonin transporter, 5-HTT, plays a key role in modulating the pulmonary vascular remodeling caused by hypoxia.

The endothelial responses to circumferential vascular stretch are poorly defined. In two different models of vascular stretch in the intact lung, Kuebler and coworkers (57) studied the effect of circumferential stretch on lung endothelial production of nitric oxide. In isolated–perfused rat lungs, increases in vascular pressure caused stretch-dependent increases in nitric oxide, which were localized to capillary endothelial cells; the response was inhibited by blockers of nitric oxide synthase. In isolated–perfused mouse lungs, vascular stretch (induced by negative-pressure ventilation) induced phosphorylation of Akt and endothelial nitric oxide synthase in lung endothelial cells; production of nitric oxide was also increased. In both models, the endothelial responses to stretch were abrogated by phosphatidylinositol-3-OH kinase inhibitors. The authors conclude that circumferential vascular stretch activates the production of nitric oxide in the pulmonary endothelial cells by a signaling cascade that involves phosphatidylinositol-3-OH kinase, Akt, and endothelial nitric oxide synthase, and that this response is independent of mechanical factors causing vascular distension.

Diagnosis.
In 374 patients referred for lung transplantation, Arcasoy and coworkers (58) assessed the accuracy of Doppler echocardiography in the diagnosis of pulmonary hypertension. Right-heart catheterization revealed pulmonary hypertension in 25% of patients (mean systolic pulmonary artery pressure, 42 mm Hg). Systolic pulmonary artery pressure could be estimated by echocardiography in 166 patients (44%). Systolic pulmonary artery pressures, estimated by echocardiography and catheterization, were correlated (r = 0.69). Of pressures estimated by echocardiography, 52% differed by more than 10 mm Hg from the value on catheterization, and 48% of patients were misclassified as having pulmonary hypertension. In diagnosing pulmonary hypertension, echocardiography had a sensitivity of 85%, specificity of 55%, positive predictive value of 52%, and negative predictive value of 87%. The authors conclude that estimates of systolic pulmonary artery pressure by Doppler echocardiography are frequently inaccurate in patients with advanced lung disease, leading to considerable over-diagnosis of pulmonary hypertension.

Treatment.
Kuhn and coworkers (59) examined the factors associated with outcome in 91 patients with pulmonary arterial hypertension treated with epoprostenol. Poor outcome was associated with older age at disease onset (hazard ratio, 3.2), World Health Organization functional class IV (hazard ratio, 3.07), and scleroderma-associated pulmonary hypertension (hazard ratio, 2.32). Hemodynamic variables at baseline or on follow up were not associated with survival. The authors conclude that epoprostenol increases survival over that predicted, and that survival is less in patients who also have scleroderma, who are older, or who are of lower functional class.

Oral sildenafil is a more potent acute pulmonary vasodilator than is inhaled nitric oxide in patients with pulmonary hypertension. In 12 patients with inoperable chronic thromboembolic pulmonary hypertension that was progressive despite long-term anticoagulation, Ghofrani and coworkers (60) assessed the effect of oral sildenafil. After 6 months of treatment, sildenafil resulted in a decrease in pulmonary vascular resistance index (1,935 to 1,361 dyn · s · cm–5), an increase in cardiac index (2.0 to 2.4 liters per minute per m2), and an increase in 6-minute walking distance (312 to 366 m). The authors conclude that oral sildenafil achieves beneficial effects in patients with chronic thromboembolic pulmonary hypertension.

Thromboembolic Disorders
To evaluate the cost-effectiveness of various strategies used to diagnose pulmonary embolism, Perrier and coworkers (61) did a formal decision analysis based on 3-month survival. All strategies were compared with a reference strategy: a ventilation–perfusion scan, followed by an angiogram if the scan was negative. For patients who had a low clinical probability, the most cost-effective strategy was D-dimer, ultrasound, and ventilation–perfusion scan—patients that had a nondiagnostic ventilation perfusion scan were left untreated. For patients who had an intermediate or high clinical probability, a fourth test was necessary: either helical computed tomography or angiography in patients with a nondiagnostic ventilation–perfusion scan, or angiography in patients with negative helical computed tomography. The authors conclude that the inclusion of helical computed tomography is cost-effective in the diagnosis of pulmonary embolism provided it is combined with D-dimer and ultrasound, but that it is not cost-effective when used alone.

Because magnetic resonance angiography does not yield optimal images in patients who cannot breath-hold, a motion-compensated projection might be an improvement. In nine pigs with artificially induced pulmonary emboli, Haage and coworkers (62) compared three imaging techniques against conventional angiography. Conventional angiography revealed 43 filling defects at lobar and segmental levels. Two independent readers achieved the following sensitivities: 72% and 70% for spiral computed tomography; 79% and 81% for magnetic resonance angiography; and 98% and 98% for real-time magnetic resonance sequence without a breath-hold. The authors conclude that real-time magnetic resonance imaging that does not require a breath-hold is comparable to conventional angiography in the detection of pulmonary angiography.

Use of femoral-vein catheters is associated with a high risk of thrombosis despite prophylactic therapy. To assess the cost-effectiveness of routine lower extremity Doppler ultrasound screening in patients with femoral vein catheters, Cox and coworkers (63) developed a decision model. The analysis was based on a hypothetical cohort of 60-year-old medical patients being treated for acute respiratory failure. The costs of the ultrasound strategy were $8,688 per quality-adjusted life-year gained, $5,305 per pulmonary embolism averted, and $99,286 per death from pulmonary embolism averted. By varying in-hospital mortality, prevalence of deep-vein thrombosis, and ultrasound accuracy, the best-case cost was $1,170 and the worst-case cost was $35,342 per quality-adjusted life-year gained. Allowing for variation in variables of uncertain value, the median cost was $12,793 per quality-adjusted life-year gained. The authors conclude that routine ultrasound screening of patients with femoral vein catheters may improve outcomes at acceptable costs.

High Altitude
Hypoxia is known to inhibit the activity and expression of ion-transport proteins of cultured alveolar epithelial cells. To determine whether in vivo hypoxia inhibits lung ion transport, Mairbaurl and coworkers (64) measured transepithelial nasal potentials before and during a stay at high altitude (4,559 m). In normoxia, total nasal potential was about 20% higher in 12 control subjects than in 10 mountaineers with a history of high-altitude pulmonary edema; the groups did not differ in nasal potentials that could be inhibited by amiloride. At high altitude, total nasal potential increased by 250% in both groups; nasal potential sensitive to amiloride decreased by about 80% solely in the control subjects, and the portion of nasal potential sensitive to chloride ion almost doubled. Because nasal dryness is common at high altitude, the effect of controlled humidity of 50% was also studied during normobaric hypoxia: no change was observed in total nasal potential or in the fractions sensitive to amiloride or chloride. The authors conclude that an increase in chloride secretion compensating for drying of the nasal mucosa is responsible for the transepithelial nasal potential at high altitude, and that changes in nasal potentials at high altitude reflect a specific response of the nasal mucosa and do not reflect the alveolar epithelium.

Sickle Cell Disease
L-Arginine is the nitrogen donor for the synthesis of nitric oxide, a potent vasodilator that is deficient in patients experiencing a sickle-cell crisis. In 10 patients with sickle cell disease and documented pulmonary hypertension, Morris and coworkers (65) found that 5 days of oral arginine decreased pulmonary artery systolic pressure from 64 to 54 mm Hg. The level of arginase was almost twice as high in the patients as in normal subjects (arginase hydrolyzes arginine and may compete with nitric oxide synthase, causing decreased production of nitric oxide). The authors conclude that L-arginine shows promise in the treatment of pulmonary hypertension associated with sickle-cell disease. An editorial commentary by Jison and Gladwin (66) accompanies this article.

More that 40% of patients who develop acute chest syndrome secondary to sickle-cell disease have fat droplets in their alveolar macrophages, which are suggestive of pulmonary fat embolism. To determine the reliability of induced sputum for diagnosing fat embolism, Lechapt and coworkers (67) did two studies. In 20 patients with acute chest syndrome, the number of Oil Red O–stained macrophages in induced sputum was correlated with the number in bronchoalveolar lavage fluid (Spearman's coefficient, 0.66). In a second group of 60 patients with episodes of acute chest syndrome, sputum induction was successful in 47 patients. A diagnosis of pulmonary fat embolism (based on 5% of macrophages staining with Oil Red O) was made in 29 of the 47 patients with acute chest syndrome (61.7%) and none of 9 patients who did not have acute chest syndrome. Compared with patients who had acute chest syndrome but did not have pulmonary fat embolism, the patients with fat embolism were more likely to have additional extrathoracic pain (76 versus 50%), neurological symptoms (7 versus 0%), abnormal transaminases (28 versus 17%), and a lower differential platelet count (–49 versus 85). The authors conclude that staining of induced sputum is a useful test for diagnosing pulmonary fat embolism in patients who have acute chest syndrome secondary to sickle-cell disease.


    LUNG TRANSPLANTATION
 TOP
 CONTENTS
 CHRONIC OBSTRUCTIVE PULMONARY...
 AIR POLLUTION
 PULMONARY VASCULAR DISORDERS AND...
 LUNG TRANSPLANTATION
 PLEURAL DISORDERS
 LUNG CANCER AND ONCOLOGIC...
 REFERENCES
 
Lung Preservation and Ischemia Reperfusion Injury
Sugita and coworkers (68) created a canine single-lung transplant model to determine the impact of transplantation-associated injury on the clearance mechanisms of pulmonary edema. After 3 hours of preservation and 4 hours of reperfusion, alveolar liquid clearance in ex vivo liquid-filled lung preparations was lower in transplanted (left) lungs than in native (right) lungs. The transplanted lung did not respond to the ß-agonist, terbutaline. In vivo studies confirmed the ex vivo results. Molecular analyses revealed a decrease in messenger RNA and protein expression for the epithelial sodium channel, but not sodium, potassium-ATPase, in the transplanted lung. The authors conclude that the injury resulting from lung preservation and transplantation causes a decrease in the ability to clear lung edema.

Inhalation of nitric oxide has been advocated as a method to prevent ischemia–reperfusion injury after lung transplantation. Meade and coworkers (69) did a randomized controlled trial of inhaled nitric oxide (22 ppm) versus placebo in 83 patients, initiated 10 minutes after reperfusion. PO2/FIO2 was equivalent in the nitric oxide and placebo groups (361 versus 351) on admission to the ICU. Severe hypoxemia (PO2/FIO2 less than 150) taken as an index of severe reperfusion injury, was present in 14.6% of the nitric oxide group and 9.5% of the control group. The nitric oxide and placebo groups had equivalent times to first trial of spontaneous breathing (medians of 25 versus 27 hours), successful extubation (32 versus 34 hours), ICU discharge (3 days for both), and hospital discharge (27 versus 29 days). Five patients in the nitric oxide and six in the placebo group died in the hospital. The authors conclude that inhaled nitric oxide shortly after reperfusion does not alter clinical outcome in patients undergoing lung transplantation. An editorial commentary by Glanville (70) accompanies this article.

Obliterative Bronchiolitis
To determine whether innate immunity contributes to the development of allograft rejection after lung transplantation, Palmer and coworkers (71) assessed the impact of two functional polymorphisms in toll-like receptor 4 associated with endotoxin hyporesponsiveness on the development of acute rejection. The polymerase chain reaction was used to screen 174 lung-transplant recipients and 157 of their cadaveric donors for the toll-like receptor 4 Asp299Gly and Thr399Ile polymorphisms. The rate of rejection at 6 months was lower in recipients (but not in donors) with the Asp299Gly or Thr399Ile alleles as compared with wild type: 29 versus 59%. The authors conclude that activation of innate immunity in lung-transplant recipients through toll-like receptor 4 contributes to the development of acute rejection after lung transplantation. An editorial commentary by Balperio (72) accompanies this article.

Noninvasive markers that predict the likelihood of acute rejection and bronchiolitis obliterans syndrome after lung transplantation have not been developed. Gimino and coworkers (73) did gene expression microarrays of bronchoalveolar cells obtained in 7 patients with acute rejection and 27 patients without rejection. Cell and differential counts were similar in the two groups. The acute rejection group exhibited upregulation of 135 genes, including genes involved in acute rejection, immune response genes with an unknown role in rejection, genes not known to have a role in rejection, and genes of unknown function. The acute rejection samples showed significant changes in gene expression for seven biological pathways. The authors conclude that microarray analysis of bronchoalveolar cells is a powerful tool for identifying genes and gene expression patterns indicative of acute rejection after lung transplantation.

To define the contributions of indirect and direct allorecognition pathways in chronic lung rejection, Chalermskulrat and coworkers (74) used the heterotopic tracheal transplantation model. Transplantation of wild-type tracheal allografts into MHC II–/– or H2-DM{alpha}–/– mice, which have different disruptions in the class II–dependent antigen process, resulted in more intact epithelium and less luminal obstruction than did grafts transplanted into wild-type or MHC I–/– allorecipients. The grafts exhibited abundant CD4+ and CD8+ cell infiltrates similar to those in control allografts. Compared with allograft control mice, MHC I–/– and MHC I/II–/–, but not MHC II–/– allografts, placed in wild-type mice demonstrated less severe rejection. The authors conclude that the indirect allorecognition pathway has the strongest influence on rejection but that the direct pathway is also sufficient to cause chronic rejection, and that MHC class I molecules are the principal alloantigens in the mouse heterotopic tracheal model of obliterative bronchiolitis.

Rejection
Statins (3-hydroxy-3-methylglutaryl coenzyme A inhibitors) lower blood cholesterol but also have immunomodulatory actions. To determine the effect of statins on outcome after lung transplantation, Johnson and coworkers (75) analyzed data on 39 allograft recipients who were prescribed statins for hyperlipidemia and 161 control recipients who did not receive statins. None of the patients started on statins during the first postoperative year developed obliterative bronchiolitis as compared with a cumulative incidence of 37% among control patients. Patients treated with statins exhibited less total cellularity and fewer inflammatory neutrophils and lymphocytes. Among double-lung recipients, patients taking statins had higher FVC (80 versus 70% predicted), FEV1 (87 versus 70% predicted), and FEV1/FVC (83 versus 79%). Six-year survival was higher in patients taking statins than in control patients: 91 versus 54%. The authors conclude that statins may improve outcome after lung transplantation.

Macrolide antibiotics have achieved beneficial actions in the treatment of panbronchiolitis in patients with cystic fibrosis. To determine whether patients with bronchiolitis obliterans syndrome would also benefit, Gerhardt and coworkers (76) administered azithromycin (250 mg three times a week for 14 weeks) to six patients with deteriorating allograft function. The six patients demonstrated a mean increase in FEV1 of 0.5 liter (range, –0.18 to 1.36 liter), representing an average improvement in FEV1 of 46%. The authors conclude that azithromycin may prove beneficial in patients with bronchiolitis obliterans following lung transplantation.

In Lymphangiomyomatosis
Lymphangiomyomatosis (LAM) has been reported to recur after lung transplantation, but it is unclear whether the recurrence arises from the patient or from the donor. Karbowniczek and coworkers (77) studied a 44-year-old woman who died of Aspergillus pneumonia at 22 months after lung transplantation for LAM. Specimens obtained from the transplanted lung (allograft) at autopsy were analyzed by microsatellite marker fingerprinting, which revealed patient-derived LAM cells. Before transplantation, a somatic one base-pair deletion in exon 18 of the TSC2 gene was identified in LAM cells (lung and lymph nodes). The same mutation was found in the recurrence of LAM, indicating that the recurrence originated in the patient. The authors conclude that histologically benign LAM cells can migrate or metastasize to lung allografts after transplantation.


    PLEURAL DISORDERS
 TOP
 CONTENTS
 CHRONIC OBSTRUCTIVE PULMONARY...
 AIR POLLUTION
 PULMONARY VASCULAR DISORDERS AND...
 LUNG TRANSPLANTATION
 PLEURAL DISORDERS
 LUNG CANCER AND ONCOLOGIC...
 REFERENCES
 
Physiology/Pathophysiology
Intercellular adhesion molecule-1 is an adhesion molecule that plays a key role in cell-cell interactions involved in the recruitment of cells and immune responses. To determine the cellular source, control and activity of soluble intercellular adhesion molecule-1, Melis and coworkers (78) did thoracenteses in 9 patients with congestive heart failure, 8 patients with tuberculosis, and 15 patients with cancer. In patients with tuberculous and malignant effusions, dimeric soluble intercellular adhesion molecule-1 was released locally in the pleural compartment. The soluble adhesion molecule was shed from pre-expressed surface intercellular adhesion molecule-1 rather than produced de novo. CD45-positive leukocytes and cytokeratin-positive epithelial and mesothelial cells expressed intercellular adhesion molecule-1, suggesting that it originates from multiple cellular sources. Pleural macrophages caused the release of soluble intercellular adhesion molecule-1 via a mechanism depending on tumor necrosis factor-{alpha}. Soluble intercellular adhesion molecule-1 interfered with conjugate formation between LAK cells and K562 cells, suggesting that the adhesion molecule plays an immunosuppressive role. The authors conclude that soluble intercellular adhesion molecule-1 is shed from the surface of pleural cells in a regulated manner and is capable of modulating the immune response in the pleural space.

To determine whether transforming growth factor-ß1 modulates fibrosis occurring in the pleural space, Sasse and coworkers (79) induced empyema in rabbits. Pleural fluid revealed increases in transforming growth factor-ß1 between the first two days and the eighth day after induction of empyema (8,100 versus 39,600 pg per ml). The level of transforming growth factor-ß1 in pleural fluid was proportional to pleural thickening (r = 0.70) and the number of fibroblasts in the visceral pleura (r = 0.68). The first increase of transforming growth factor-ß1 in pleura fluid (third day) occurred before the increase in fibroblasts (fourth day) and pleural thickness (fourth day). The authors conclude that transforming growth factor-ß1 increases in pleural fluid as fibrosis develops in experimental empyema and the increase is proportional to the extent of pleural space fibrosis.

Diagnostic Techniques
In 113 patients with suspected pleural tuberculosis who were unable to produce sputum spontaneously, Conde and coworkers (80) determined the diagnostic reliability of induced sputum. A final diagnosis of pleural tuberculosis was made in 84 (71 HIV-seronegative) patients. Histopathological examination of pleura biopsy tissue had a diagnostic yield of 78% (66 of 84). Bacteriologic yields were 62% for pleural biopsy, 12% for pleural fluid, and 52% for sputum cultures obtained by sputum induction. The yield for cultures of induced sputum was equivalent in patients without radiologic involvement (other than a pleural effusion) and in patients with parenchymal involvement suggestive of pulmonary tuberculosis: 55% versus 45%. The authors conclude that culture of induced sputum is positive in 52% of patients with suspected pleural tuberculosis who are unable to produce sputum spontaneously. An editorial commentary by Menzies (81) accompanies this article.

In a pulmonary perspective, Heffner and colleagues (82) present a meta-analysis on use of likelihood ratios for diagnosing pleural effusions.

Pleurodesis
In a rabbit model, Montes and coworkers (83) investigated the local and distant effects of instilling two doses of talc into the pleura cavity. A high dose of talc (200 mg per kg) caused frequent extrapulmonary talc deposition: ipsilateral lung (70%), contralateral lung (55%), mediastinum (90%), pericardium (30%), and liver (25%). A low dose of talc (50 mg per kg) caused less frequent extrapulmonary deposition: ipsilateral lung (10%), mediastinum (20%), and none in the contralateral lung, pericardium, or liver. The high dose caused a rapid systemic inflammatory response, involving massive accumulation of neutrophils and macrophages in lung tissue. Pulmonary expression of matrix metalloproteinases 2 and 9 was upregulated in both lungs in a dose-dependent manner soon after talc instillation. Fibrotic thickening of the visceral pleura and foreign-body granulomas were proportional to the dose of talc. The authors conclude that pleurodesis induced by a high dose of talc causes both pulmonary and extrapulmonary talc deposition associated with acute and chronic inflammatory responses.


    LUNG CANCER AND ONCOLOGIC DISORDERS
 TOP
 CONTENTS
 CHRONIC OBSTRUCTIVE PULMONARY...
 AIR POLLUTION
 PULMONARY VASCULAR DISORDERS AND...
 LUNG TRANSPLANTATION
 PLEURAL DISORDERS
 LUNG CANCER AND ONCOLOGIC...
 REFERENCES
 
Diagnosis
Up to half of patients with histologically normal lymph nodes have micrometastases detected by molecular techniques. To determine whether the expression of human telomerase reverse transcriptase (found by the reverse transcription-polymerase chain reaction) could detect micrometastatic disease, Wallace and coworkers (84) did fine-needle aspiration of lymph nodes (under endoscopic ultrasound) in 39 patients with non–small cell lung cancer and 12 control subjects (being evaluated for benign pancreatic or biliary disease). Human telomerase reverse-transcriptase was expressed in 10 of 16 pathologically positive lymph nodes, 18 of 57 pathologically negative lymph nodes from cancer patients, and 0 of 14 negative nodes from control subjects. Of 18 patients without pathologic evidence of mediastinal disease, 5 (28%) expressed telomerase in at least one lymph node (the clinical significance of this observation is not known). The authors conclude that ultrasound-guided fine-needle aspiration combined with molecular detection of telomerase expression can detect cancer-specific messenger RNA in lymph nodes. An editorial commentary by Massion and Carbone (85) accompanies this article.

To determine whether the use of automated quantitative image cytometry of sputum cells as the first screening method results in superior detection of lung cancer, McWilliams and coworkers (86) studied 561 current or former smokers (with a smoking history at least 30 pack years). Sputum atypia, defined as at least 5 cells with abnormal DNA content, was found in 423 of the subjects (75.4%). Noncalcified pulmonary nodules were found in 259 of the subjects (46%). Of 14 primary lung cancers diagnosed (10 by computed tomography and 4 by autofluorescence bronchoscopy), 13 were found in subjects with sputum atypia. Automated quantitative image cytometry of sputum cells improved the cancer detection rate from 1.8 to 3.1%. A computed tomography scan on its own would have missed 29% of cancers. The authors conclude that 93% of lung cancers can be detected by finding atypical cells by automated quantitative image cytometry of sputum cells whereas 29% of lung cancers do not appear on computed tomography. An editorial commentary by Henschke (87) accompanies this article.

Staging of patients with lung cancer is undertaken to minimize futile thoracotomies and yet not deny possible curative surgery. To assess the usefulness of endoscopic ultrasound with fine-needle aspiration under conscious sedation in providing tissue proof of inoperability in a single staging test, Fritscher-Ravens and coworkers (88) studied a consecutive cohort of 79 potentially operable patients with suspected or proven lung cancer. Thirty-nine patients were found inoperable. Sensitivities of three diagnostic procedures were: endoscopic ultrasound, 63%; computed tomography, 43%; and positron-emission tomography, 68%. Specificities were: endoscopic ultrasound, 100%; computed tomography, 91%, and positron emission tomography, 72%. The costs were: computed tomography alone, $549; computed tomography plus positron emission tomography, $2,799; and endoscopic ultra-fine needle aspiration plus computed tomography, $1,695. The authors conclude that the superior specificity and relatively low costs of endoscopic ultrasound combined with fine-needle aspiration make it a valuable method for identifying patients with inoperable lung cancer. An editorial commentary by Kern (89) accompanies this article.

Studies of Molecular Mechanisms
Breast cancer metastases appear to be regulated by a member of the CXC chemokine family, CXCL12 (or stromal cell-derived factor-1), and its cognate receptor, CXCR4. Phillips and coworkers (90) investigated the role of this chemokine and its receptor in mediating metastases of non–small cell lung cancer. Tumor specimens resected from patients with non–small cell lung cancer and cell lines of non–small cell lung cancer expressed the receptor, CXCR4, but not the chemokine, CXCL12. The cell lines underwent chemotaxis in response to CXCL12. Activation of cell lines by the biologic axis formed by CXCR4 and CXCL12 mobilized intracellular calcium and activated mitogen-activated protein kinase; phosphorylation of extracellular signal-related kinase-1/2 was enhanced without change in proliferation or apoptosis. In a murine model, target organs that are the preferred destination of human non–small cell lung cancer metastases elaborated higher levels of CXCL12 than did the primary tumor (suggesting a chemotactic gradient). In mice with severe combined immunodeficiency that expressed non–small cell lung cancer, administration of specific neutralizing antibodies against CXCL12 abrogated organ metastases without affecting primary tumor-derived angiogenesis. The authors conclude that the biologic axis formed by the chemokine, CXCL12, and its receptor, CXCR4, regulates metastasis of non–small cell lung cancer.

Leukemia
Azoulay and coworkers (91) report 20 patients with respiratory impairment as the presenting manifestation of undiagnosed acute monocytic leukemia. All of the patients had myeloid leukemia of the AML5 subtype. The median leukocyte count was 98,250 per mm3 and all but one patient had circulating monocytic cells. Patients presented with a respiratory rate of 33 breaths per minute, PO2 (room air) of 45 mm Hg, and variable changes on chest X-ray. Alveolar hemorrhage was the main finding on bronchoalveolar lavage. Respiratory function deteriorated in every patient with a few hours of starting chemotherapy. Ten of 15 patients requiring mechanical ventilation died. The authors conclude that acute pulmonary infiltration resulting in respiratory failure can be the presenting manifestation of acute monocytic leukemia, and that patients require intensive management in anticipation of deterioration after commencing chemotherapy.

Stem Cell Transplantation
New onset of airflow obstruction, also called bronchiolitis obliterans, is a significant complication of myeloablative allogenic hematopoietic stem cell transplantation. To characterize the epidemiology of this complication, Chien and coworkers (92) evaluated data on 1,131 patients undergoing myeloablative allogenic hematopoietic stem cell transplantation over a 12-year period. Airflow obstruction was defined as a decline in FEV1 of more than 5% per year with the lowest post-transplant FEV1/FVC ratio of less than 0.80. This criterion was met by 26% of the overall group and by 32% of patients who developed chronic graft-versus-host disease. New onset of airflow obstruction was associated with greater age at transplantation, lower FEV1/FVC before transplantation, history of acute and chronic graft-versus-host disease, and respiratory viral infection in the first 100 days after transplantation. Attributable mortality for airflow obstruction was 9% at 3 years, 12% at 5 years, and 18% at 10 years. Attributable mortality for the subpopulation with chronic graft-versus-host disease was 22% at 3 years, 27% at 5 years, and 40% at 10 years. The authors conclude that the new onset of airflow obstruction among patients undergoing myeloablative allogenic hematopoietic stem-cell transplantation is much commoner than previously suspected, and that it has a high mortality even after controlling for other factors. An editorial commentary by Folz (93) accompanies this article.

It is possible that many of the tissues of the body may be actively replaced by circulating stem cells after hematopoietic stem cell transplantation. To determine whether tissues of the human lung might be derived from nonpulmonary sources, Suratt and coworkers (94) examined lung specimens from a cohort of 46 women who received stem cells from male donors. Tissue samples (obtained at diagnostic lung biopsy or autopsy) from three women were suitable for examination. Assessment for cytokeratin (epithelium) and platelet endothelial cell adhesion molecule (endothelium) was used in part to identify male cells. Some 36 to 42% of the endothelial cells and 3 to 8% of the epithelial cells were of donor origin. The authors conclude that chimerism (localization of donor-derived cells) occurs in the human lung after hematopoietic stem-cell transplantation. An editorial commentary by Robbins (95) accompanies this article.


    FOOTNOTES
 
Supported by a Merit Review grant from the Veterans Affairs Research Service

Conflict of Interest Statement: M.J.T. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript.


    REFERENCES
 TOP
 CONTENTS
 CHRONIC OBSTRUCTIVE PULMONARY...
 AIR POLLUTION
 PULMONARY VASCULAR DISORDERS AND...
 LUNG TRANSPLANTATION
 PLEURAL DISORDERS
 LUNG CANCER AND ONCOLOGIC...
 REFERENCES
 

  1. Sanders MH, Newman AB, Haggerty CL, Redline S, Lebowitz M, Samet J, O'Connor GT, Punjabi NM, Shahar E. Sleep and sleep-disordered breathing in adults with predominantly mild obstructive airway disease. Am J Respir Crit Care Med 2003;167:7–14.[Abstract/Free Full Text]
  2. Fleetham JA. Is chronic obstructive pulmonary disease related to sleep apnea–hypopnea syndrome? Am J Respir Crit Care Med 2003;167:3–4.[Free Full Text]
  3. Snider GL. Nosology for our day: its application to chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2003;167:678–683.[Free Full Text]
  4. Gildea TR, Shermock KM, Singer ME, Stoller JK. Cost-effectiveness analysis of augmentation therapy for severe {alpha}1–antitrypsin deficiency. Am J Respir Crit Care Med 2003;167:1387–1392.[Abstract/Free Full Text]
  5. Churg A, Wang RD, Xie C, Wright JL. {alpha}1-Antitrypsin ameliorates cigarette smoke-induced emphysema in the mouse. Am J Respir Crit Care Med 2003;168:199–207.[Abstract/Free Full Text]
  6. Stockley RA. "Knock-out" mouse: down but not out. Am J Respir Crit Care Med 2003;168:145–146.[Free Full Text]
  7. American Thoracic Society/European Respiratory Society statement. standards for the diagnosis and management of individuals with {alpha}1-antitrypsin deficiency. Am J Respir Crit Care Med 2003;168:818–900.[Free Full Text]
  8. Fabbri LM, Romagnoli M, Corbetta L, Casoni G, Busljetic K, Turato G, Ligabue G, Ciaccia A, Saetta M, Papi A. Differences in airway inflammation in patients with fixed airflow obstruction due to asthma or chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2003;167:418–424.[Abstract/Free Full Text]
  9. Qiu Y, Zhu J, Bandi V, Atmar RL, Hattotuwa K, Guntupalli KK, Jeffery PK. Biopsy neutrophilia, neutrophil chemokine and receptor gene expression in severe exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2003;168:968–975.[Abstract/Free Full Text]
  10. Saetta M, Baraldo S, Zuin R. Neutrophil chemokines in severe exacerbations of chronic obstructive pulmonary disease: fatal chemo-attraction? Am J Respir Crit Care Med 2003;168:911–913.[Free Full Text]
  11. Churg A, Wang RD, Tai H, Wang X, Xie C, Dai J, Shapiro SD, Wright JL. Macrophage metalloelastase mediates acute cigarette smoke-induced inflammation via tumor necrosis factor-{alpha} release. Am J Respir Crit Care Med 2003;167:1083–1089.[Abstract/Free Full Text]
  12. Snider GL. Understanding inflammation in chronic obstructive pulmonary disease: the process begins. Am J Respir Crit Care Med 2003;167:1045–1046.[Free Full Text]
  13. Wang RD, Tai H, Xie C, Wang X, Wright JL, Churg A. Cigarette smoke produces airway wall remodeling in rat tracheal explants. Am J Respir Crit Care Med 2003;168:1232–1236.[Abstract/Free Full Text]
  14. Betsuyaku T, Tanino M, Nagai K, Nasuhara Y, Nishimura M, Senior RM. Extracellular matrix metalloproteinase inducer is increased in smokers' bronchoalveolar lavage fluid. Am J Respir Crit Care Med 2003;168:222–227.[Abstract/Free Full Text]
  15. Choe KH, Taraseviciene-Stewart L, Scerbavicius R, Gera L, Tuder RM, Voelkel NF. Methylprednisolone causes matrix metalloproteinase-dependent emphysema in adult rats. Am J Respir Crit Care Med 2003;167:1516–1521.[Abstract/Free Full Text]
  16. Ryu JH, Myers JL, Swensen SJ. Bronchiolar disorders. Am J Respir Crit Care Med 2003;168:1277–1292.[Abstract/Free Full Text]
  17. Jeffery P, Holgate S, Wenzel S. Methods for the assessment of endobronchial biopsies in clinical research: application to studies of pathogenesis and the effects of treatment. Am J Respir Crit Care Med 2003;168:S1–17.[Free Full Text]
  18. Kinnula VL, Crapo JD. Superoxide dismutases in the lung and human lung diseases. Am J Respir Crit Care Med 2003;167:1600–1619.